[HTML][HTML] Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies

G Pistritto, D Trisciuoglio, C Ceci, A Garufi… - Aging (albany …, 2016 - ncbi.nlm.nih.gov
Apoptosis is a form of programmed cell death that results in the orderly and efficient removal
of damaged cells, such as those resulting from DNA damage or during development …

Molecular mechanisms of cisplatin resistance

L Galluzzi, L Senovilla, I Vitale, J Michels, I Martins… - Oncogene, 2012 - nature.com
Platinum-based drugs, and in particular cis-diamminedichloroplatinum (II)(best known as
cisplatin), are employed for the treatment of a wide array of solid malignancies, including …

Systems biology of cisplatin resistance: past, present and future

L Galluzzi, I Vitale, J Michels, C Brenner… - Cell death & …, 2014 - nature.com
The platinum derivative cis-diamminedichloroplatinum (II), best known as cisplatin, is
currently employed for the clinical management of patients affected by testicular, ovarian …

BCL-2 protein family: attractive targets for cancer therapy

D Kaloni, ST Diepstraten, A Strasser, GL Kelly - Apoptosis, 2023 - Springer
Acquired resistance to cell death is a hallmark of cancer. The BCL-2 protein family members
play important roles in controlling apoptotic cell death. Abnormal over-expression of pro …

Mechanisms of resistance to cisplatin and carboplatin

DJ Stewart - Critical reviews in oncology/hematology, 2007 - Elsevier
While cisplatin and carboplatin are active versus most common cancers, epithelial
malignancies are incurable when metastatic. Even if an initial response occurs, acquired …

Cisplatin resistance: preclinical findings and clinical implications

B Köberle, MT Tomicic, S Usanova, B Kaina - Biochimica et Biophysica …, 2010 - Elsevier
Cisplatin is used for the treatment of many types of solid cancers. While testicular cancers
respond remarkably well to cisplatin, the therapeutic efficacy of cisplatin for other solid …

Bcl-2 antiapoptotic family proteins and chemoresistance in cancer

S Maji, S Panda, SK Samal, O Shriwas, R Rath… - Advances in cancer …, 2018 - Elsevier
Cancer is a daunting global problem confronting the world's population. The most frequent
therapeutic approaches include surgery, chemotherapy, radiotherapy, and more recently …

Mechanisms of drug resistance in ovarian cancer and associated gene targets

KL Alatise, S Gardner, A Alexander-Bryant - Cancers, 2022 - mdpi.com
Simple Summary When tumors become resistant to chemotherapeutics, alternative
treatment strategies must be explored. Gene targeting provides a personalized and …

Ovarian cancer stem cells and targeted therapy

V Keyvani, M Farshchian, SA Esmaeili, H Yari… - Journal of ovarian …, 2019 - Springer
Background Ovarian cancer has the highest ratio of mortality among gynecologic
malignancies. Chemotherapy is one of the most common treatment options for ovarian …

A multi-omic single-cell landscape of human gynecologic malignancies

MJ Regner, K Wisniewska, S Garcia-Recio… - Molecular cell, 2021 - cell.com
Deconvolution of regulatory mechanisms that drive transcriptional programs in cancer cells
is key to understanding tumor biology. Herein, we present matched transcriptome (scRNA …